BRCA2 and colorectal carcinoma: In assessing whether ADAR1 SL effects extended to BRCA2-mutant cells, we found that ADAR1 silencing elicited SL in two different BRCA2-isogenic systems: human BRCA2-knockout colorectal carcinoma cells (DLD1)27 and mouse Brca2-knockout 4T1 cells25 (Fig. 2D; and Supplementary Fig. 2G–J, 3A-F).